Brokerages expect Dynavax Technologies Corporation (NASDAQ:DVAX) to announce $0.30 earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dynavax Technologies’ earnings. The highest EPS estimate is $0.95 and the lowest is ($0.35). Dynavax Technologies posted earnings per share of ($0.56) in the same quarter last year, which would suggest a positive year-over-year growth rate of 153.6%. The company is expected to announce its next earnings results on Monday, March 12th.
According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($1.36) per share for the current year, with EPS estimates ranging from ($1.75) to ($0.25). For the next year, analysts expect that the company will post earnings of ($1.19) per share, with EPS estimates ranging from ($1.65) to ($0.59). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company’s revenue was down 68.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.90) earnings per share.
Shares of Dynavax Technologies (DVAX) traded down $0.35 during trading hours on Friday, hitting $17.40. 1,687,900 shares of the company were exchanged, compared to its average volume of 1,874,170. Dynavax Technologies has a 12-month low of $3.70 and a 12-month high of $24.45.
A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in Dynavax Technologies by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the last quarter. Nationwide Fund Advisors increased its holdings in shares of Dynavax Technologies by 2.5% during the 2nd quarter. Nationwide Fund Advisors now owns 28,359 shares of the biopharmaceutical company’s stock valued at $274,000 after purchasing an additional 692 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in shares of Dynavax Technologies by 3.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 939 shares in the last quarter. American International Group Inc. increased its holdings in shares of Dynavax Technologies by 7.1% during the 1st quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 1,584 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Dynavax Technologies by 16.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,700 shares in the last quarter. Institutional investors own 70.61% of the company’s stock.
TRADEMARK VIOLATION WARNING: “$0.30 Earnings Per Share Expected for Dynavax Technologies Corporation (DVAX) This Quarter” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/06/0-30-earnings-per-share-expected-for-dynavax-technologies-corporation-dvax-this-quarter.html.
About Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.